Monday, October 22, 2012

Common Parenting FAQs - Can I breastfeed my baby during the time I have Viral Fever?

Dr. Can i breastfeed my during viral fever i m very scared to feed him?
Yes you can, 
It's actually good for the baby, since the antibodies that protect the child can travel through the Breast milk and help ward off infections,
Warm regards
Dr Gaurav Gupta

Saturday, October 20, 2012

'Mother's Kiss' May Dislodge Objects Stuck in Child's Nose


October 15, 2012 — The "mother's kiss" technique helped dislodge foreign objects from children's noses in 60% of reported cases, according to a literature analysis published online October 15 in theCanadian Medical Association Journal.
"The mother's kiss appears to be a safe and effective technique for first-line treatment in the removal of a foreign body from the nasal cavity," Stephanie Cook, BM BCh, from Buxted Medical Centre in the United Kingdom, and colleagues write. "In addition, it may prevent the need for general anesthesia in some cases."
The positive pressure technique involves a trusted caregiver sealing his or her mouth over the child's mouth and rapidly exhaling while occluding the unaffected nostril. Closure of the glottis limits the risk for barotrauma, and the low pressure generated is comparable to that of a sneeze (60 mm Hg).
To determine whether "mother's kiss" was effective, researchers from the United Kingdom and Australia performed a systematic search of current literature, identifying 6 relevant case series and 2 case reports involving children aged 1 to 8 years. Fourteen articles were excluded, including 4 review articles, 7 articles not written as case series, and 3 articles that consisted of a technique description only.
Data analysis revealed that mother's kiss was effective 59.9% of the time (95% confidence interval [CI], 52% - 67%), a success rate found to be independent of object type (smooth, 73% [95% CI, 56% - 86%] vs irregular, 77% [95% CI, 62% - 87%]).
Most foreign objects (87%, 27/31) documented in the studies were visible before removal attempts. Two studies concluded that fully obstructing objects were much more likely to be propelled out of the nose than those allowing air to pass, and that irregularly shaped objects tended to be easier to grasp.
The authors also found that implementation of the technique may prevent the need for general anesthesia in some cases. Of the 2 studies that included relevant information, one reported a 90% decrease in anesthesia use during 6-month periods before and after implementation of the technique (from 32.5% to 3.2%), and the other reported a lower rate of general anesthesia when the technique was attempted first (11.9% vs 18.8%; P = .34).
No adverse events were reported despite theoretical risks for epistaxis, ruptured tympanic membrane, or pneumothorax.
Insufficient data were provided in the studies with respect to determining technique success relative to the length of obstruction time, object visibility, or prior attempts at removal.
"Further studies are needed to compare different positive-pressure techniques, and to test their efficacy in specific situations addressing how long the foreign body has been lodged and its location in the nasal cavity," the authors write. They also note that future research should involve preregistered, large, consecutive, prospective case series to reduce the effect of selective reporting.
CMAJ. Published online October 15, 2012. Abstract
Commentary: A fascinating study regarding a unique way in which parents can actually treat their child effectively while potentially avoiding need for traumatic medical intervention.

Tuesday, October 09, 2012

Trial Suggests Prevnar May Also Protect Ages 18 to 49


(Reuters) Oct 05 - Pfizer Inc said a late-stage trial of its vaccine to protect against pneumococcal pneumonia suggested it would also work in adults aged 18-49, thereby possibly expanding its sales.
The vaccine, Prevnar 13, which already has $3.5 billion in annual sales from its use in adults over age 50 and children under age five, is designed to protect against pneumonia, meningitis and other infections caused by 13 strains of Streptococcus pneumoniae.
Pfizer said Prevnar 13 met the main goal of the late-stage study by showing that the immune response to the vaccine in the 18- to 49-year-old age group was not inferior when compared with the response in the 60-to 64-year-old group.
Pfizer said on Thursday that the favorable results from the study will support both its recent European Union application to market the product for the 18-49 age group, as well as applications it plans to make in other countries.
A competing vaccine from GlaxoSmithKline, Synflorix, protects against 10 strains of S. pneumoniae.
Commentary: It's always good to know about the clinical effectiveness of a vaccine in a defined age-group. However, two notes of caution are warranted....
1) It is very important to know the disease burden in the defined age group, more so in case of an expensive vaccine like Prevenar, since that would help decide the cost-effectiveness. How commonly do these problems occur in 18-49 year old people? Not very often, in my opinion.
2) The study talks about immune response only, which is NOT the same thing as clinical effectiveness. This means that the antibody responses that are measured do not necessarily result in people being actually protected against these illnesses.
Overall, given that the illnesses that are being protected against (pneumonia, meningitis, sepsis) do not occur frequently in the age group of 18-49 years, and the vaccine is prohibitively expensive, I do not think this study  would have a major impact in developing countries including India.